Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Rayer C, Nachury M, Bourreille A, Roblin X, Peyrin-Biroulet L, Viennot S, Flamant M, Laharie D, Caron B, Dewitte M, Siproudhis L, Fumery M, Bouguen G. Rayer C, et al. BMC Gastroenterol. 2023 Feb 2;23(1):31. doi: 10.1186/s12876-022-02636-9. BMC Gastroenterol. 2023. PMID: 36732693 Free PMC article. No abstract available.
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study.
Martin A, Nachury M, Peyrin-Biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N, Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A; GETAID-Vedo-STOP Study Group. Martin A, et al. J Crohns Colitis. 2020 Jul 30;14(7):896-903. doi: 10.1093/ecco-jcc/jjaa005. J Crohns Colitis. 2020. PMID: 31930285 Free article.
Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID.
Bouhnik Y, Pineton de Chambrun G, Lambert J, Nachury M, Seksik P, Altwegg R, Vuitton L, Stefanescu C, Nancey S, Aubourg A, Serrero M, Filippi J, Desseaux K, Viennot S, Abitbol V, Boualit M, Bourreille A, Giletta C, Buisson A, Roblin X, Dib N, Malamut G, Amiot A, Fumery M, Louis E, Elgharabawy Y, Peyrin-Biroulet L; MICA-GETAID Study Group. Bouhnik Y, et al. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3365-3378.e5. doi: 10.1016/j.cgh.2023.01.013. Epub 2023 Jan 31. Clin Gastroenterol Hepatol. 2023. PMID: 36731588 Free article.
Etrasimod for the treatment of ulcerative colitis.
Wils P, Peyrin-Biroulet L. Wils P, et al. Immunotherapy. 2023 Apr;15(5):311-321. doi: 10.2217/imt-2022-0255. Epub 2023 Feb 15. Immunotherapy. 2023. PMID: 36789612 Review.
Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies.
Panaccione R, Louis E, Colombel JF, D'Haens G, Peyrin-Biroulet L, Dubinsky M, Takeuchi K, Rubin DT, Kalabic J, Chien KB, Chen S, Cheng L, Zhang Y, Duan WR, Vladea R, Hecht PM, Morisset P, Schreiber S, Ferrante M. Panaccione R, et al. Among authors: peyrin biroulet l. J Crohns Colitis. 2025 Jan 13:jjaf005. doi: 10.1093/ecco-jcc/jjaf005. Online ahead of print. J Crohns Colitis. 2025. PMID: 39804294
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
Sands BE, Panaccione R, D'Haens G, Schreiber S, Jairath V, DuVall A, Kierkus J, Walczak M, Naik S, Gilder K, Lindstrom B, Ogilvie K, Sandborn WJ, Vermeire S, Rubin DT, Peyrin-Biroulet L, Danese S. Sands BE, et al. Among authors: peyrin biroulet l. Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00386-8. doi: 10.1016/S2468-1253(24)00386-8. Online ahead of print. Lancet Gastroenterol Hepatol. 2025. PMID: 39793589
1,105 results